Carcinogen
WHO aspartame declaration draws mixed reaction from cancer experts
Leaders of the oncology community expressed mixed reaction to International Agency for Research on Cancer’s declaration of aspartame as possibly carcinogenic to humans.
WHO: Aspartame potentially carcinogenic
One of the most popular artificial sweeteners is a potential carcinogen and people should consume only 40 mg/kg body weight daily, according to WHO committees.
Pfizer voluntarily recalls five more lots of BP medication for carcinogen risk
Pfizer issued a voluntarily nationwide recall of five lots of quinapril HCl/hydrochlorothiazide tablets due to the presence of a nitrosamine known to be carcinogenic in high doses.
Pfizer recalls certain lots of blood pressure medications due to carcinogen risk
Pfizer has issued a voluntarily recall of certain lots of quinapril HCl/hydrochlorothiazide tablets and additional lots distributed by Greenstone due to high levels of a nitrosamine known to be carcinogenic in high doses.
Lupin recalls irbesartan tablets due to possible carcinogenic contamination
Lupin is voluntarily recalling batches of irbesartan and irbesartan/hydrochlorothiazide tablets after an analysis revealed that certain tested active pharmaceutical ingredient batches had too much N-nitrosoirbesartan.
Angiotensin receptor antagonist use decreased after recalls for potentially carcinogenic impurities
The use of angiotensin II receptor antagonists, particularly generic valsartan, losartan and irbesartan, decreased since being recalled for potentially carcinogenic impurities, according to a research letter published in JAMA.
‘So many are dying’: Screening guidelines miss lung cancer among first responders
Occupational exposure to carcinogens often is overshadowed by smoking as a risk factor for lung cancer, yet it has been linked to an estimated 30% of lung cancers. Moreover, those who experience this exposure, including first responders, frequently are missed by lung cancer screening guidelines from the U.S. Preventive Services Task Force.
ED visits spike, prescribing patterns change in wake of valsartan recall
PHILADELPHIA — When multiple generic valsartan products were recalled worldwide in July 2018 due to the presence of a carcinogenic contaminant, valsartan dispensing immediately decreased. However, there was an immediate spike in ED visits for hypertension and incomplete replacement with alternative products in some patients, according to new data presented at the American Heart Association Scientific Sessions.
FDA warns Mylan over valsartan manufacturing violations
The FDA announced it issued a warning letter to Mylan Laboratories Limited over violations of current good manufacturing practice observed during an inspection of a drug manufacturing facility in India.